Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Government to Increase Review Fee for New Generic Drugs from 630,000 Yen to 940,000 Yen
August 1, 2014
- JPA’s Abe Makes Chuikyo Debut, Says No to Annual Drug Price Revisions
July 31, 2014
- Regulatory Review Trend in Japan Signals Pharmas’ Shift to Cancer Drugs: Jiho Tally
July 30, 2014
- MHLW Bulletin Notifies of Revised Package Inserts Warning Concurrent Use of ARBs, ACE Inhibitors
July 30, 2014
- NIBIO Initiates Support for Applied Research on 15 Promising Drug Seeds with Goal of First Licensing Agreement by FY2015
July 30, 2014
- MHLW to Review Criteria for Clinical Research Core Hospitals by April
July 29, 2014
- Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25
July 29, 2014
- Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official
July 29, 2014
- PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8
July 29, 2014
- Editor’s Pick: Five Healthcare News Headlines for July14 - July 25
July 28, 2014
- Health Minister Calls for Strict Compliance with Transparency Guidelines
July 28, 2014
- Japan OKs Guidelines for FY2015 Budget Requests, Natural Rise of 830 Billion Yen in Social Security Costs
July 28, 2014
- PDMA to Issue Practical Notification on Submission of Electronic Applications for Approval Next January at Earliest
July 28, 2014
- MHLW Suggests Regulation for Research Likely to Be Used in Ads
July 25, 2014
- Cabinet Approves Health, Medical Strategy
July 24, 2014
- Toshihiko Takeda Appointed Councilor in Charge of Health Insurance
July 24, 2014
- PMDA Reviewing Infliximab for Risk of Rhabdomyolysis
July 24, 2014
- PAFSC’s First Committee to Discuss MSD’s Insomnia Drug on Aug. 1
July 24, 2014
- Ex-Novartis Employee Indicted on Additional Charges, Prosecutors to Wind Up Probe: Reports
July 23, 2014
- Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…